Opportunity Information: Apply for PAR 13 201
Apply for PAR 13 201
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Paul Calabresi Career Development Award for Clinical Oncology (K12)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.398 Cancer Research Manpower 93.399 Cancer Control.
- This funding opportunity was created on Apr 17, 2013 and posted on Apr 17, 2013.
- Applicants must submit their applications by Jun 18, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: Small businesses Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments County governments Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Independent school districts State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program. The applicant institution must have a strong and high quality research program in the area(s) proposed under this FOA and must have the requisite faculty and facilities on site to conduct the proposed institutional program. In many cases, it is anticipated that the proposed program will complement other ongoing career development programs occurring at the applicant institution and that a substantial number of program faculty will have active research projects in which participating scholars may gain relevant experiences consistent with their research interests and goals. Institutions with existing programs must explain what distinguishes this program from the others, how their programs will synergize with one another, if applicable, and make it clear that the pool of faculty, potential scholars, and resources are robust enough to support additional programs.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Paul Calabresi Career Development Award for Clinical Oncology (K12) is a National Institutes of Health (NIH) institutional training and career development grant designed to strengthen the pipeline of cancer clinical trials researchers. The central aim is to help institutions build structured, mentored career development programs that prepare early stage investigators to become independent, patient-oriented clinical researchers, with a particular emphasis on the skills needed to design, launch, and run therapeutic clinical trials. In practical terms, the program is meant to increase the number of well-trained clinicians and Ph.D. scientists who can develop and test cancer treatment strategies in real-world patient settings and who can function effectively within team-based research environments.
This opportunity specifically targets the training of individuals who intend to lead or substantially contribute to clinical therapeutic research protocols across the spectrum of trial development, including pilot and Phase I studies (often focused on safety, dosing, and feasibility), Phase II studies (focused on preliminary efficacy and further safety), and Phase III trials (focused on comparative effectiveness at scale). The award is oriented toward patient-oriented cancer research, meaning studies that directly involve human subjects and address clinically meaningful questions about cancer therapy. The program also emphasizes career development support for investigators who have made a clear commitment to patient-oriented research as the core of their long-term career trajectory, rather than treating clinical investigation as a side activity.
Because this is a K12 institutional award, the applicant is not an individual researcher but an eligible organization proposing to run a comprehensive career development program. The institution is expected to recruit and support a cohort of “scholars†(trainees) who will receive protected time, mentoring, and research experiences aligned with clinical oncology trials and translational therapeutic research. While the specific structure can vary by institution, these programs typically include a combination of mentored research experiences, didactic instruction relevant to clinical trial methods (such as protocol development, biostatistics, ethics, regulatory compliance, data management, and safety monitoring), and professional development activities that help scholars transition to independent funding and leadership roles in oncology research.
Eligible applicant organizations are broad and include public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status, other than institutions of higher education), for-profit organizations, small businesses, and many levels of government entities (state, county, city/township, special districts, independent school districts), as well as tribal governments and tribal organizations. The eligibility language also explicitly includes a range of mission-focused institutions and communities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and Asian American and Native American Pacific Islander-serving institutions (AANAPISIs), along with U.S. territories or possessions and certain eligible federal agencies. In short, NIH structured eligibility broadly, but it also set clear expectations that the sponsoring institution must be capable of delivering a high-quality clinical research career development program.
A key requirement is institutional commitment. The sponsoring organization must be able to assure strong support for the proposed K12 program, including adequate staffing, facilities, and educational resources. NIH expects the applicant institution to have an established, high-quality research base in the cancer areas it proposes to emphasize, with the necessary on-site faculty expertise and infrastructure to support patient-oriented therapeutic research and clinical trials activity. This is not intended for organizations that would have to build the research ecosystem from scratch; rather, it supports institutions that can provide scholars with meaningful, hands-on experiences embedded in active research programs and multidisciplinary teams.
NIH also anticipates that a K12 program will often coexist with other training and career development programs at the same institution. If an institution already has related programs, it must explain what is distinct about the Calabresi K12 program, how it will complement or synergize with existing efforts, and why the institution has a sufficiently large and robust pool of faculty mentors, scholars, and resources to support an additional program without diluting quality. This requirement is essentially about demonstrating that the new K12 is additive and strategically designed, not duplicative, and that it will materially improve the institution’s ability to develop independent clinical oncology investigators.
From an administrative standpoint, the opportunity was issued as Funding Opportunity Number PAR-13-201 under NIH’s discretionary grant authority, with an activity focus spanning education and health and aligning with multiple cancer-related CFDA program areas, including cancer treatment, detection and diagnosis, biology, control, and research workforce development. The FOA was posted on April 17, 2013, with the final listed application due date of June 18, 2015, and an archive date of July 19, 2015, indicating it is no longer active. The listing indicates no cost sharing or matching requirement, which typically reduces barriers for institutions by not requiring them to contribute a mandated percentage of program costs, although NIH still expects substantial non-monetary institutional commitment (like protected time, mentoring capacity, and research infrastructure). The listing also shows an “Award Ceiling†of $50,000 as captured in the source data, though in practice K12 budgets are often structured around scholar support and program administration as defined in the full FOA.
Overall, the Paul Calabresi K12 is best understood as an institutional mechanism to professionalize and accelerate the development of clinical oncology trialists. Its purpose is not simply to provide research exposure, but to produce investigators who can independently conceptualize therapeutic questions, translate them into rigorous clinical trial protocols, navigate the ethical and regulatory landscape of human subjects research, collaborate within multidisciplinary teams, and ultimately improve cancer treatment through patient-centered clinical investigation. For reference, the full archived announcement was posted by NIH at http://grants.nih.gov/grants/guide/pa-files/PAR-13-201.html, and technical access issues were directed to the NIH Office of Extramural Research (OER) webmaster contact listed in the opportunity.
Frequently Asked Questions (FAQs)
What is the Paul Calabresi Career Development Award for Clinical Oncology (K12)?
The Paul Calabresi Career Development Award for Clinical Oncology (K12) is a National Institutes of Health (NIH) institutional training and career development grant. It is designed to strengthen the pipeline of cancer clinical trials researchers by supporting institutions that run structured, mentored career development programs in clinical oncology research.
What is the main goal of this K12 program?
The central aim is to help institutions build structured, mentored programs that prepare early stage investigators to become independent, patient-oriented clinical researchers. A major emphasis is on building the skills needed to design, launch, and run therapeutic clinical trials and to work effectively in team-based research environments.
Who applies for the K12 award: individuals or institutions?
This is a K12 institutional award, so the applicant is an eligible organization (institution), not an individual researcher. The institution proposes and administers the program and recruits a cohort of scholars (trainees).
Who are the “scholars†supported by an institutional K12 program?
Scholars are the trainees recruited and supported by the institution’s K12 program. They typically receive protected time, mentoring, and research experiences focused on clinical oncology trials and translational therapeutic research.
What types of research does the program emphasize?
The program is oriented toward patient-oriented cancer research. That means studies that directly involve human subjects and address clinically meaningful questions about cancer therapy, especially therapeutic clinical trials research.
What kinds of clinical trials are included within the scope of training?
The opportunity targets training for individuals who intend to lead or substantially contribute to clinical therapeutic research protocols across the trial development spectrum, including pilot and Phase I studies (often focused on safety, dosing, and feasibility), Phase II studies (focused on preliminary efficacy and further safety), and Phase III trials (focused on comparative effectiveness at scale).
Does the program focus on clinical investigation as a primary career path?
Yes. The program emphasizes career development support for investigators who have made a clear commitment to patient-oriented research as the core of their long-term career trajectory, rather than treating clinical investigation as a side activity.
What does a typical K12 career development program include?
While the structure can vary by institution, programs typically combine mentored research experiences with didactic instruction in clinical trial methods and professional development activities. The didactic content commonly includes areas such as protocol development, biostatistics, ethics, regulatory compliance, data management, and safety monitoring, alongside activities that help scholars transition to independent funding and leadership roles.
What is meant by “therapeutic clinical trials†in this context?
In this opportunity, therapeutic clinical trials refer to clinical studies aimed at developing and testing cancer treatment strategies in real-world patient settings, with training geared toward designing and running those studies and contributing meaningfully to therapeutic research protocols.
What kinds of organizations are eligible to apply?
Eligibility is broad and includes public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status, other than institutions of higher education), for-profit organizations, small businesses, and multiple levels of government entities (state, county, city/township, special districts, independent school districts). It also includes tribal governments and tribal organizations, U.S. territories or possessions, and certain eligible federal agencies.
Are minority-serving and mission-focused institutions explicitly included in eligibility?
Yes. The eligibility language explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and Asian American and Native American Pacific Islander-serving institutions (AANAPISIs).
What does NIH expect regarding institutional commitment?
NIH expects strong institutional support for the proposed K12 program, including adequate staffing, facilities, and educational resources. The sponsoring organization must be able to assure strong support and demonstrate capability to deliver a high-quality clinical research career development program.
Does the institution need an existing cancer research base to be competitive?
Yes. NIH expects the applicant institution to have an established, high-quality research base in the cancer areas it proposes to emphasize, including on-site faculty expertise and infrastructure that can support patient-oriented therapeutic research and clinical trials activity.
Is this funding intended to help an organization build a research ecosystem from scratch?
No. The opportunity is described as supporting institutions that can provide scholars with meaningful, hands-on experiences embedded in active research programs and multidisciplinary teams, rather than organizations that would need to build the research ecosystem from scratch.
How should an institution address existing training or career development programs on campus?
If the institution already has related programs, it must explain what is distinct about the Calabresi K12 program, how it will complement or synergize with existing efforts, and why the institution has a sufficiently large and robust pool of faculty mentors, scholars, and resources to support an additional program without diluting quality.
Why does NIH care about whether the K12 is distinct from other programs?
The requirement is meant to show that the K12 is additive and strategically designed, not duplicative, and that it will materially improve the institution’s ability to develop independent clinical oncology investigators.
What is the funding opportunity number for this announcement?
The funding opportunity was issued as Funding Opportunity Number PAR-13-201.
When was the FOA posted, and is it still active?
The FOA was posted on April 17, 2013. The final listed application due date was June 18, 2015, and the archive date was July 19, 2015, indicating that the opportunity is no longer active.
Is there a cost sharing or matching requirement?
The listing indicates there is no cost sharing or matching requirement. Even so, NIH still expects substantial institutional commitment through non-monetary support such as protected time, mentoring capacity, and research infrastructure.
What award ceiling is shown in the source listing?
The listing shows an “Award Ceiling†of $50,000 as captured in the source data. The description also notes that, in practice, K12 budgets are often structured around scholar support and program administration as defined in the full FOA.
What broader NIH program areas does this opportunity align with?
The activity focus spans education and health and aligns with multiple cancer-related CFDA program areas, including cancer treatment, detection and diagnosis, biology, control, and research workforce development.
Where can the full archived NIH announcement be found?
The archived announcement was posted by NIH at http://grants.nih.gov/grants/guide/pa-files/PAR-13-201.html.
Who is referenced for technical access issues related to the announcement?
The opportunity notes that technical access issues were directed to the NIH Office of Extramural Research (OER) webmaster contact listed in the opportunity.
What is the overall purpose of the Paul Calabresi K12 mechanism?
Overall, it is an institutional mechanism meant to professionalize and accelerate the development of clinical oncology trialists. It aims to produce investigators who can independently conceptualize therapeutic questions, translate them into rigorous clinical trial protocols, navigate ethical and regulatory requirements for human subjects research, collaborate in multidisciplinary teams, and improve cancer treatment through patient-centered clinical investigation.
Browse more opportunities from the same category: Education Health
Next opportunity: Evidence Based Laboratory Medicine Laboratory Medicine Best Practices Systematic Review Recommendations Evaluation
Previous opportunity: R3 State Wildlife Grant Program (TO STATE FG AGENCIES ONLY)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 201
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 201) also looked into and applied for these:
| Funding Opportunity |
|---|
| Symptom Management in HIV Infected Individuals with Comorbid Conditions (R01) Apply for PA 13 210 Funding Number: PA 13 210 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Symptom Management in HIV Infected Individuals with Comorbid Conditions (R21) Apply for PA 13 211 Funding Number: PA 13 211 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Innovative Measurement Tools for Community Engaged Research Efforts (R01) Apply for PA 13 209 Funding Number: PA 13 209 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative Measurement Tools for Community Engaged Research Efforts (R21) Apply for PA 13 212 Funding Number: PA 13 212 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Limited Competition Fogarty HIV Research Training Program for Low and Middle Income Country Institutions (D43) Apply for PAR 13 126 Funding Number: PAR 13 126 Agency: National Institutes of Health Category: Education Health Funding Amount: $282,000 |
| Medications Development Centers of Excellence Cooperative Program (U54) Apply for RFA DA 14 004 Funding Number: RFA DA 14 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R01) Apply for RFA DA 14 005 Funding Number: RFA DA 14 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R21) Apply for RFA DA 14 006 Funding Number: RFA DA 14 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Integration and Analysis of Diverse HIV Associated Data (R03) Apply for RFA MH 14 200 Funding Number: RFA MH 14 200 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Research Center of Excellence Grant Program (P50) Apply for PAR 13 222 Funding Number: PAR 13 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| FY14 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 14 008 Funding Number: RFA DA 14 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Integrating Substance Abuse Prevention and Treatment within HIV/AIDS Service Delivery Settings (R01) Apply for RFA DA 14 011 Funding Number: RFA DA 14 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| HIV/AIDS and Substance Use among Black/African American Women and Young MSM (R01) Apply for RFA DA 14 010 Funding Number: RFA DA 14 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV/AIDS and Substance Use Among the Homeless and Unstably Housed (R01) Apply for RFA DA 14 009 Funding Number: RFA DA 14 009 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comorbid HIV, Chronic Pain, and Substance Use among Older Adults (R21) Apply for RFA DA 14 012 Funding Number: RFA DA 14 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research to Characterize and Reduce Stigma to Improve Health (R21) Apply for PA 13 246 Funding Number: PA 13 246 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research to Characterize and Reduce Stigma to Improve Health (R03) Apply for PA 13 247 Funding Number: PA 13 247 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Research to Characterize and Reduce Stigma to Improve Health (R01) Apply for PA 13 248 Funding Number: PA 13 248 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Adult Brain Tumor Consortium (ABTC) (UM1) Apply for RFA CA 13 501 Funding Number: RFA CA 13 501 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,000,000 |
| Limited Competition Pediatric Brain Tumor Consortium (UM1) Apply for RFA CA 13 502 Funding Number: RFA CA 13 502 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,590,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 201", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.